Alector, Inc. (FRA:0Z2)

Market Cap	173.64M +8.6%
Revenue (ttm)	58.85M +12.3%
Net Income	-91.82M
EPS	-0.92
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	1.610
Previous Close	1.620
Day's Range	1.610 - 1.610
52-Week Range	0.815 - 2.860
Beta	n/a
RSI	60.11
Earnings Date	Feb 26, 2026

About Alector

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company’s products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 156
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0Z2

Financial Performance

In 2024, Alector's revenue was $100.56 million, an increase of 3.60% compared to the previous year's $97.06 million. Losses were -$119.05 million, -8.70% less than in 2023.

Financial numbers in USD